Correspondence 0001193125-24-025156 from Metagenomi Therapeutics, Inc. (MGX)
Metagenomi Therapeutics, Inc.
Date: Feb. 6, 2024 · CIK: 0001785279 · Accession: 0001193125-24-025156
AI Filing Summary & Sentiment
File numbers found in text: 333-276413
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Jenn Do, Angela Connell, Tyler Howes and Suzanne Hayes Re: Metagenomi, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-276413
Dear Ladies and Gentlemen,
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Metagenomi, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to February 8, 2024 at 4:00 p.m. Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Edwin M. O’Connor at (212) 813–8853 or Justin S. Platt at (212) 459-7340.
If you have any questions regarding this request, please contact Justin S. Platt of Goodwin Procter LLP at (212) 459 7340.
Sincerely,
METAGENOMI, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR February 6, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Jenn Do, Angela Connell, Tyler Howes and Suzanne Hayes Re: Metagenomi, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-276413 Dear Ladies and Gentlemen, Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Metagenomi, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to February 8, 2024 at 4:00 p.m. Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Edwin M. O’Connor at (212) 813–8853 or Justin S. Platt at (212) 459-7340. If you have any questions regarding this request, please contact Justin S. Platt of Goodwin Procter LLP at (212) 459 7340. Sincerely, METAGENOMI, INC. /s/ Brian C. Thomas Brian C. Thomas Chief Executive Officer cc: Brian C. Thomas, Ph.D., Metagenomi, Inc. Simren Delaney, Ph.D., LLM, Metagenomi, Inc. Matthew L. Wein, J.D., Metagenomi, Inc. Mitchell S. Bloom, Goodwin Procter LLP Edwin M. O’Connor, Goodwin Procter LLP Justin S. Platt, Goodwin Procter LLP